CytomX Therapeutics Inc
$ 5.44
-2.51%
24 Feb - close price
- Market Cap 945,449,000 USD
- Current Price $ 5.44
- High / Low $ 5.74 / 5.44
- Stock P/E 18.60
- Book Value 0.65
- EPS 0.30
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.67 %
- 52 Week High 6.35
- 52 Week Low 0.40
About
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$9.00
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CTMX
2026-02-22 08:02:10
Dr. Amy Peterson, President and COO of CytomX Therapeutics, is recognized as an innovator in oncology for her contributions to developing cutting-edge cancer treatments. Her work focuses on utilizing CytomX's Probody platform to target tumor cells effectively while minimizing harm to healthy tissue. Peterson's leadership and commitment to patients have driven significant advancements in therapies, including two FDA-approved cancer drugs during her previous roles.
2026-02-19 10:28:10
CytomX Therapeutics (CTMX) is advancing its PROBODY masking platform with two clinical-stage programs, CX-2051 and CX-801, targeting cancer. CX-2051, an ADC for EpCAM-positive cancers, showed a 28% confirmed response rate in a Phase 1 colorectal cancer study, with further data and combination trials planned. CX-801, an interferon alpha-2b therapeutic, is also in Phase 1 trials for melanoma, demonstrating tolerability, and initial combination data with KEYTRUDA is expected by late 2026.
2026-02-17 10:02:33
Barclays has increased its price target for CytomX Therapeutics, Inc. (CTMX) to $10 from $8 while maintaining an Overweight rating, following a similar move by Piper Sandler and new coverage initiation by Guggenheim with a Buy rating, both also setting a $10 price target. The positive outlook is primarily driven by promising Phase I data on varsetatug maseatecan, which demonstrated significant anti-tumor activity in metastatic colorectal cancer patients. CytomX is expected to provide further updates on its expansion cohorts soon.
2026-02-17 09:58:03
Barclays has increased its price target for CytomX Therapeutics, Inc. (CTMX) to $10 from $8, maintaining an Overweight rating, following a fourth-quarter earnings preview for the biotechnology group. This update comes after Piper Sandler also raised its target to $10 from $6.50 due to promising initial Phase I data for varsetatug maseatecan, which showed a 28% overall response rate and 94% disease control rate in metastatic colorectal cancer. Guggenheim analyst Michael Schmidt also initiated coverage with a Buy rating and a $10 price target, citing "extraordinary" antitumor activity.
2026-02-17 09:57:31
Barclays has raised its price target on CytomX Therapeutics, Inc. (CTMX) to $10 from $8, maintaining an Overweight rating, following a fourth-quarter earnings preview for the biotechnology group. This update comes after Piper Sandler also increased its price target to $10 from $6.50 based on promising Phase I data for varsetatug maseatecan, which showed a 28% overall response rate and 94% disease control rate in metastatic colorectal cancer. Guggenheim analyst Michael Schmidt also initiated coverage with a Buy rating and a $10 price target, citing "extraordinary" antitumor activity.
2026-02-16 21:58:03
Barclays has raised its price target on CytomX Therapeutics, Inc. (CTMX) to $10 from $8 and maintained an Overweight rating, ahead of the company's fourth-quarter earnings report. This follows a similar upgrade by Piper Sandler to $10 from $6.50 based on promising Phase I data for varsetatug maseatecan in metastatic colorectal cancer, and new coverage initiated by Guggenheim with a Buy rating and a $10 price target. CytomX develops conditionally activated biologics for oncology and preclinical applications.
